Pacific Biosciences of California Inc (PACB) Stock AnalysisPACBPacific Biosciences of California Inc

Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops, and manufactures sequencing solutions. Its products and technology include HiFi long-read sequencing technology, which addresses a set of applications including human germline sequencing, plant and animal sciences, infectious disease, microbiology, oncology, and other applications. Its sequencing technology supports oncology research by enabling analysis of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), providing researchers with insight into cancer biology. It focuses on creating sequencing systems to provide customers with a view of genomes, transcriptomes, and epigenomes. Its customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations (CROs), pharmaceutical companies, and agricultural companies. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Given the current price of $2.33, the stock is not a strong buy at this moment. The RSI is at 52.275, indicating a neutral momentum, and the forward P/E is at 0, suggesting uncertainty in future earnings. The recent revenue guidance cut to $155 million to $165 million raises concerns about financial stability. However, the stock has shown a significant 79.23% increase over the last 20 days, indicating potential for recovery. The main risk is the net income loss of $44.7 million reported in Q2 2026, which could impact investor confidence.

6 analysts cover PACB: 2 rate it Buy, 4 Hold and 0 Sell. The average price target is 2.40.